UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Cancer science, 2017-10, Vol.108 (10), p.2069-2078

2017

Volltextzugriff (PDF)

Flexibility and Cell Permeability of Cyclic Ras-Inhibitor Peptides Revealed by the Coupled Nosé–Hoover Equation

Journal of chemical information and modeling, 2021-04, Vol.61 (4), p.1921-1930

2021

Volltextzugriff (PDF)

Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines

Bioorganic & medicinal chemistry letters, 2020-10, Vol.30 (20), p.127475-127475, Article 127475

2020

Volltextzugriff (PDF)

Quantitative Structure‐activity Relationship (QSAR) Models for Docking Score Correction

Molecular informatics, 2017-01, Vol.36 (1-2), p.n/a

2017

Volltextzugriff (PDF)

Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17

Anti-cancer drugs, 2012-01, Vol.23 (1), p.119-130

2012

Volltextzugriff (PDF)

Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation

Bioorganic & medicinal chemistry letters, 2024-01, Vol.98, p.129575-129575, Article 129575

2024

Volltextzugriff (PDF)

Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity

Bioorganic & medicinal chemistry, 2024-09, Vol.111, p.117862, Article 117862

2024

Volltextzugriff (PDF)

Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator

Bioorganic & medicinal chemistry, 2017-07, Vol.25 (13), p.3540-3546

2017

Volltextzugriff (PDF)

Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.756-757

2022

Volltextzugriff (PDF)

Optimization of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors, Leading to the Potent DS08701581

ACS medicinal chemistry letters, 2024-07, Vol.15 (7), p.1010-1016

2024

Volltextzugriff (PDF)

Discovery of DS79932728: A Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease

ACS medicinal chemistry letters, 2021-01, Vol.12 (1), p.121-128

2021

Volltextzugriff (PDF)

Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity

ACS medicinal chemistry letters, 2019-05, Vol.10 (5), p.737-742

2019

Volltextzugriff (PDF)

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Blood, 2017-12, Vol.130, p.2073-2073

2017

Volltextzugriff (PDF)

A novel inhibitor stabilizes the inactive conformation of MAPK‐interacting kinase 1

Acta crystallographica. Section F, Structural biology communications, 2018-03, Vol.74 (3), p.156-160

2018

Volltextzugriff (PDF)

Discovery of imidazo[1,2- b]pyridazine derivatives as IKKβ inhibitors. Part 1: Hit-to-lead study and structure–activity relationship

Bioorganic & medicinal chemistry letters, 2010-09, Vol.20 (17), p.5113-5118

2010

Volltextzugriff (PDF)

Design and Synthesis of Carboxylate Inhibitors for Matrix Metalloproteinases

Chemical and Pharmaceutical Bulletin, 2001, Vol.49(10), pp.1272-1279

2001

Volltextzugriff (PDF)

Discovery of imidazo[1,2- b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo

Bioorganic & medicinal chemistry letters, 2011-02, Vol.21 (3), p.904-908

2011

Volltextzugriff (PDF)

Abstract B133: Antitumor effects of novel high-hydrophilic and non-ATP-competitive MEK1/2 inhibitor SMK-17

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B133-B133

2011

Volltextzugriff (PDF)

Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship

Bioorganic & medicinal chemistry letters, 2010-09, Vol.20 (17), p.5113-5118

2010

Volltextzugriff (PDF)

ChemInform Abstract: Design and Synthesis of Carboxylate Inhibitors for Matrix Metalloproteinases

ChemInform, 2002-03, Vol.33 (12), p.no-no

2002

Volltextzugriff (PDF)

Fabrication of complete 8 in. stencil mask for electron projection lithography

Journal of Vacuum Science & Technology B: Microelectronics and Nanometer Structures, 2002-11, Vol.20 (6), p.3010-3014

2002

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(6)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Flexibility and Cell Permeability of Cyclic Ras-Inhibitor Peptides Revealed by the Coupled Nosé–Hoover Equation

Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines

Quantitative Structure‐activity Relationship (QSAR) Models for Docking Score Correction

Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17

Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation

Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity

Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator

Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Optimization of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors, Leading to the Potent DS08701581

Discovery of DS79932728: A Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease

Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

A novel inhibitor stabilizes the inactive conformation of MAPK‐interacting kinase 1

Discovery of imidazo[1,2- b]pyridazine derivatives as IKKβ inhibitors. Part 1: Hit-to-lead study and structure–activity relationship

Design and Synthesis of Carboxylate Inhibitors for Matrix Metalloproteinases

Discovery of imidazo[1,2- b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo

Abstract B133: Antitumor effects of novel high-hydrophilic and non-ATP-competitive MEK1/2 inhibitor SMK-17

Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship

ChemInform Abstract: Design and Synthesis of Carboxylate Inhibitors for Matrix Metalloproteinases

Fabrication of complete 8 in. stencil mask for electron projection lithography

Aktive Filter

Suchergebnisse filtern